ribavirin has been researched along with pf 00868554 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hammond, JL; Jagannatha, S; Kantaridis, C; Neelakantan, S; Purohit, VS; Simpson, P; Thompson, R; Troke, PJ; Wagner, F | 1 |
| Appleby, TC; Bidgood, AM; Byun, D; Canales, E; Clarke, MO; Doerffler, E; Eng, S; Fenaux, M; Hashash, A; Krawczyk, SH; Lazerwith, SE; Leavitt, SA; Lee, YJ; Lew, W; Liu, Q; Mabery, EM; Matles, M; Mertzman, M; Morganelli, P; Murray, BP; Mwangi, J; Tian, Y; Watkins, WJ; Xu, L; Ye, H; Zhang, J | 1 |
2 trial(s) available for ribavirin and pf 00868554
| Article | Year |
|---|---|
Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrones; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome; Triazoles; Viral Nonstructural Proteins | 2011 |
Preclinical characterization of GS-9669, a thumb site II inhibitor of the hepatitis C virus NS5B polymerase.
Topics: Animals; Antiviral Agents; Cell Line, Tumor; Dogs; Drug Resistance, Viral; Furans; Hepacivirus; Humans; Interferon-alpha; Male; Mutation; Polymorphism, Single Nucleotide; Pyrones; Rats; Rats, Sprague-Dawley; Ribavirin; RNA-Dependent RNA Polymerase; Thiophenes; Triazoles; Viral Nonstructural Proteins | 2013 |